Odyssey Therapeutics, Inc. (ODTX)

Market Cap	992.87M
Revenue (ttm)	99,000 -96.7%
Net Income	-160.03M
EPS	-14.05
Shares Out	47.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112,053
Open	21.67
Previous Close	21.58
Day's Range	20.43 - 23.08
52-Week Range	15.10 - 23.03
Beta	n/a
Analysts	Strong Buy
Price Target	33.00 (+59.27%)
Earnings Date	Sep 17, 2026

About ODTX

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 8, 2026
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: ODTX
• Website: https://odysseytx.com

Financial Performance

In 2025, Odyssey Therapeutics's revenue was $2.98 million, a decrease of -33.45% compared to the previous year's $4.47 million. Losses were -$148.65 million, 14.0% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for ODTX stock is "Strong Buy." The 12-month stock price target is $33.0, which is an increase of 59.27% from the latest price.

Price Target

$33.0

(59.27% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 13, 2026

Data Sources Report a data error